Phase 1/2 study of peptide vaccination associated with CT-GM-01, a galactomannan oligomer that inhibits galectin-3, in patients with advanced metastatic melanoma.
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Galactomannan C (Primary) ; MAGE-A3 peptide vaccine (Primary) ; NA17-A2 peptide vaccine (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 15 Jan 2014 Status changed from recruiting to suspended, as reported by a Galectin Therapeutics media release.
- 29 Nov 2012 New source identified and integrated (ClinicalTrials.gov record NCT01723813).
- 11 Oct 2012 New source identified and integrated (European Clinical Trials Database record EudraCT2010-018638-29).